Early-Life Gut Microbiota & The Immune system in T1D
Pleun de Groen, Samantha C. Gouw, Nordin M.J. Hanssen, Max Nieuwdorp and Elena Rampanelli
Early-Life Gut Microbiota: Education of the Immune System and Links to Autoimmune Diseases. Microorganisms 2026 Jan 16;14:210.
The first years of life represent a critical window for immune system development. The gut microbiota plays a central role in this process: the bacteria colonising the infant gut "educate" the immune system and lay the foundation for immunological tolerance. When this process is disrupted — by caesarean delivery, antibiotic exposure, or formula feeding — the risk of paediatric autoimmune disease increases. This review article, authored by researchers from Amsterdam UMC and Diabeter Centre Amsterdam, synthesises current evidence on how the early-life gut microbiota influences immune maturation and what interventions may help restore it.
The authors conducted a comprehensive literature review based on systematic searches of the PubMed database up to October 2025, prioritising findings from human cohorts and clinical trials to ensure translational and clinical relevance. Both original research articles and reviews published in English were included.
Key findings:
- Early colonisation follows distinct phases: The gut microbiota progresses through four stages after birth, from an Enterobacteriaceae-dominated initial phase to a stable adult-like composition by around 31 months, each with specific immune consequences.
- Disruptions have lasting effects: Caesarean delivery, perinatal antibiotics, and formula feeding deplete key bacteria such as Bifidobacterium and Bacteroides and reduce short-chain fatty acid (SCFA) production, impairing regulatory T cell (Treg) induction and inflammation control.
- Early dysbiosis is linked to multiple autoimmune diseases: Type 1 diabetes, inflammatory bowel disease, coeliac disease, and juvenile idiopathic arthritis all show overlapping microbiome alterations: reduced diversity, loss of SCFA producers, and enrichment of pro-inflammatory taxa.
- Maternal factors matter: Maternal nutrition, antibiotic use, and health status shape the newborn's initial colonisation. Immunoglobulins and metabolites transferred via the placenta and breast milk actively influence neonatal immune development.
- Interventions can partially restore the microbiome: Probiotics, synbiotics, vaginal microbial transfer, and maternal faecal transplantation can partially normalise disrupted microbiota. Maternal faecal transplantation showed the most comprehensive and sustained effects in a proof-of-concept study.
- Prevention of autoimmune disease has not yet been demonstrated: No study has directly shown that microbiome interventions prevent autoimmune disease onset. Microbiome normalisation remains the primary reported outcome.
- Long-term research is urgently needed: Longitudinal studies tracking autoimmune outcomes following early microbiome intervention are essential to establish true preventive value.
The evidence reviewed makes a compelling case that the early-life microbiome–immune interface is a promising target for autoimmune disease prevention. Shared dysbiosis patterns across multiple paediatric autoimmune conditions point to common mechanisms — impaired Treg induction, reduced SCFA signalling, and increased gut permeability — that could in principle be addressed through early intervention. Translating microbiome normalisation into measurable reductions in autoimmune disease incidence, however, remains the critical next step, requiring both individual-level microbiome characterisation and longitudinal studies with sufficient follow-up to capture clinical endpoints.
Concluding, the authors state
"A better understanding of the early-life microbiome–immune axis is essential for developing targeted preventive strategies. Future research must prioritize longitudinal evaluation of autoimmune outcomes after microbiome modulation to reduce the burden of chronic immune-mediated diseases."
Please click here for the full-text version of the paper.